Ocumension Therapeutics (HKG:1477) obtained approval to carry out a real world study of OT-703 (ILUVIEN) in Boao Lecheng International Medical Tourism Pilot Zone in Hainan Province, China, a Tuesday Hong Kong bourse filing said.
OT-703 is an injectable, non-biodegradable fluocinolone acetate intravitreal implant for the treatment of diabetic macular edema.
In April 2021, the drugmaker had obtained exclusive licensed rights from Alimera Sciences for the development and commercialization of ILUVIEN in Greater China, South Korea and 11 countries in Southeast Asia.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。